Delmer Dee Raibourn III
@Avidity Partners Management Lp
Latest period2024 - Q3ReportedManaged Assets$1.96BTotal holdings81
Assets growth rate-16.7%Assets growth rate (2-Q avg)-20.41%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Avidity Partners Management Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 81 positions.
Assets under management
The assets under management (AUM) of Avidity Partners Management Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.96B in assets, with a quarterly growth rate of -16.7% and a 2-quarter average growth rate of -20.41%. The portfolio is managed by Delmer Dee Raibourn III, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
DHRDanaher Corporation
| 1.35% | $26.412M 95,000 shares@ $278.02 avg price | Decreased -36.66% |
JANXJanux Therapeutics Inc
| 1.31% | $25.532M 562,000 shares@ $45.43 avg price | Decreased -33.11% |
NMRANeumora Therapeutics Inc.
| 1.22% | $23.778M 1.8M shares@ $13.21 avg price | |
KYMRKymera Therapeutics Inc
| 1.21% | $23.665M 500,000 shares@ $47.33 avg price | New Position |
BHVNBiohaven Ltd
| 1.19% | $23.236M 465,000 shares@ $49.97 avg price | Increased 3.34% |
BMRNBiomarin Pharmaceutical Inc
| 1.15% | $22.493M 320,000 shares@ $70.29 avg price | New Position |
ARGXArgenx Se
| 1.06% | $20.707M 38,200 shares@ $542.08 avg price | Decreased -36.85% |
INCYIncyte Corp
| 1.04% | $20.366M 308,110 shares@ $66.1 avg price | Decreased -41.75% |
ABBVAbbvie Inc
| 1.01% | $19.748M 100,000 shares@ $197.48 avg price | Decreased -64% |
ORKAOruka Therapeutics Inc
| 0.99% | $19.386M 790,926 shares@ $24.51 avg price | New Position |